Key Influencer in the Anti-Rabies Serum Market 2025: The Rise In The Prevalence Of Dog Bites Propelling The Growth Of The Anti-Rabies Serum Market Driver

What combination of drivers is leading to accelerated growth in the anti-rabies serum market?
The growing incidence of dog bites is anticipated to drive the expansion of the anti-rabies serum market in the future. Dog bites, which include injuries sustained when a person is bitten or scratched by a dog, can range from mild to severe. These bites may lead to grave wounds, infections, and even the transmission of diseases like rabies in some instances. Timely and effective prevention and medical intervention are crucial in reducing the risks associated with dog bites. Various factors are contributing to the increase in dog bites, such as greater urbanization resulting in more interactions between humans and dogs, an increase in the number of uncontrolled or inadequately trained dogs, and lack of sufficient knowledge about dog behavior and how to prevent bites. The rise in incidences of dog bites has led to a boost in demand for anti-rabies serum, since its prompt application is essential to prevent the onset of rabies in those who may have been exposed to infected animals. For instance, in 2023, it was reported by the American Veterinary Medical Association, a non-profit organization in the US, that the average cost for dog bite insurance claims was $58,545. Insurers paid a whopping $1.12B in liability claims connected to dog bites and related injuries in 2023, a near 10% increase in dog bite claims. Hence, the heightened prevalence of dog bites is fueling the growth of the anti-rabies serum market.

Get Your Anti-Rabies Serum Market Report Here:
https://www.thebusinessresearchcompany.com/report/anti-rabies-serum-global-market-report

What is the projected compound annual growth rate (CAGR) of the anti-rabies serum market from 2025 to 2034, and what factors influence it?
The market size for anti-rabies serum has seen robust growth in recent times. The market which was $1.42 billion in 2024 is expected to reach $1.5 billion in 2025, at a compound annual growth rate (CAGR) of 5.7%. This impressive growth in the past period can be due to an increase in animal populations, the broadening of vaccination programs, enhanced diagnostics, a surge in travel and migration, and an upward trend in public health initiatives as well as a rising number of wildlife encounters.

The market for anti-rabies serum is projected to witness substantial growth in the coming years, with its size predicted to hit $1.85 billion in 2029, growing at a compound annual growth rate (CAGR) of 5.4%. This surge during the forecast period is credited to the increasing frequency of animal bites, amplified funds for rabies studies, escalated recognition of zoonotic diseases, advancements in serum storage and handling, along with augmented support for initiatives to control rabies. Emerging trends in the forecast period comprise the formulation of novel serum variants, improvements in medical infrastructure, technological breakthroughs in serum production, the introduction of alternative delivery systems, and the creation of quick diagnostic kits.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20468&type=smp

How are the latest trends influencing the growth of the anti-rabies serum market?
The anti-rabies serum market is observing the trend of major firms forming strategic alliances to bolster product development and broaden their market presence. Strategic alliances are a practice where firms tap into one another's capabilities and assets to reap mutual rewards and success. As an example, Kedrion S.p.A, a biopharmaceutical company based in the US, forged a partnership with Kamada, a biopharmaceutical company from Israel, in July 2023. The arrangement revolved around the distribution of KEDRAB (Rabies Immune Globulin [Human]) in the US and played a crucial role in co-development and licensing of the product in the U.S., while also promoting awareness about the disease. This collaboration has shown positive effects in safeguarding individuals from severe and possible fatal conditions after exposure to rabid animal bites.

What are the major segments of the anti-rabies serum market and their role in driving growth?
The anti-rabies serum market covered in this report is segmented -

1) By Type: Human Anti-rabies Immunoglobulin, Equine Anti-rabies Immunoglobulin
2) By Dosage And Form: Vials, Prefilled Syringes
3) By Route of Administration: Intravenous, Intramuscular
4) By End User: Hospitals, Clinics, Veterinary Hospitals

Subsegments:
1) By Human Anti-Rabies Immunoglobulin: Monovalent Human Anti-Rabies Immunoglobulin, Polyvalent Human Anti-Rabies Immunoglobulin, Intramuscular Human Anti-Rabies Immunoglobulin, Intravenous Human Anti-Rabies Immunoglobulin, Freeze-Dried Human Anti-Rabies Immunoglobulin
2) By Equine Anti-Rabies Immunoglobulin: Freeze-Dried Equine Anti-Rabies Immunoglobulin, Liquid Equine Anti-Rabies Immunoglobulin, Monovalent Equine Anti-Rabies Immunoglobulin, Polyvalent Equine Anti-Rabies Immunoglobulin

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20468

Which regions are key players in the growth of the anti-rabies serum market?
North America was the largest region in the anti-rabies serum market in 2024. The regions covered in the anti-rabies serum market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the key firms paving the way for growth in the anti-rabies serum market?
Major companies operating in the anti-rabies serum market are Merck & Co Inc., Sanofi SA, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, HCX Pharmaceuticals LLP, Intas Pharmaceuticals Ltd, Bavarian Nordic AS, Serum Institute of India Pvt Ltd., Bharat Serums And Vaccines Limited, Indian Immunologicals Ltd., Bharat Biotech., National Institute of Health Islamabad, ViNS Bioproducts Ltd., Shanghai Serum Bio-technology, Premium Serums and Vaccines Pvt Ltd ., Congruent Pharmachem, Haffkine Bio Pharmaceutical Corporation Limited, LEXICARE PHARMA PVT. LTD., Avin Darou, Central Research Institute Kasauli, Vigilomed Pharmaceuticals

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=20468&type=smp

What Is Covered In The Anti-Rabies Serum Global Market Report?

•Market Size Forecast: Examine the anti-rabies serum market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the anti-rabies serum market for a structured understanding.
•Key Players Overview: Analyze major players in the anti-rabies serum market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the anti-rabies serum market.
•Segment Contributions: Evaluate how different segments drive overall growth in the anti-rabies serum market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the anti-rabies serum market.
•Industry Challenges: Identify potential risks and obstacles affecting the anti-rabies serum market.
•Competitive Landscape: Review strategic developments in the anti-rabies serum market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.